Polaris Group announced that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus...
Norgine B.V. has announced new positive data from the phase III MORA study for NER 1006 (1 litre PEG and...
The results from the Phase IIb EMERGE clinical trial conducted by BMS showed treatment with the investigational compound PEG-Interferon lambda...
Shire PLC has announced that the FDA has accepted the Biologics License Application (BLA) for calaspargase pegol (Cal-PEG; SHP663). The...
Fidmi Medical Ltd. a portfolio company of The Trendlines Group Ltd., received 510(k) regulatory clearance from the FDA for its...